title: Ornidazole-based sequential therapy is not effective in Helicobacter pylori eradication in children.
abstract: OBJECTIVE
  Sequential therapy is one of the recent answers given to the problem of increasing antibiotic resistance and decreasing eradication rates of Helicobacter pylori infection. The aim of this study is to compare the ornidazole-based sequentialtherapy with the standard triple therapy in Helicobacter pylori eradication.
  
  
  METHODS
  Children aged 4-18 years diagnosed with Helicobacter pylori infection based on histology and at least one of 13 C urea breath test and rapid urease test positivity were included in the study. Children were randomized to standard triple therapy with amoxicillin, clarithromycin, and lansoprazole for 14 days and sequential therapy with amoxicillin and lansoprazole for the first 5 days and clarithromycin, ornidazole and lansoprazole for another 5 days in 2:3 randomization. At the end of the treatment, families were contacted by phone, and side effects of and the compliance to the treatment were noted. Patients were requested to do 13 C urea breath test 6-8 weeks after the treatment.
  
  
  RESULTS
  Sixty-one children were included for the final analysis. Per-protocol eradication rates were 48.6% for sequential therapy group and 54.2% for standard triple therapy group. Intention to treat eradication rates were 40.9% and 46.0%, respectively. There were no differences between eradication rates in the two study groups. Side effect rates were also similar between the two groups.
  
  
  CONCLUSIONS
  Ornidazole-based sequential therapy did not show any superiority compared to the standard triple treatment in children with Helicobacter pylori infection.
authors.affiliation: Hacettepe University School of Medicine, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Ankara, Turkey.
authors.forename: Gökhan
authors.initials: G
authors.lastname: Baysoy
authors.forename: İnci Nur
authors.initials: İN
authors.lastname: Saltık Temızel
authors.forename: Nuray
authors.initials: N
authors.lastname: Uslu
authors.forename: Necati
authors.initials: N
authors.lastname: Balamtekın
authors.forename: Hülya
authors.initials: H
authors.lastname: Demır
authors.forename: Figen
authors.initials: F
authors.lastname: Gürkan
authors.forename: Hasan
authors.initials: H
authors.lastname: Özen
authors.forename: Yakut
authors.initials: Y
authors.lastname: Akyön
authors.forename: Aysel
authors.initials: A
authors.lastname: Yüce
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D009950:Ornidazole / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D009950:Ornidazole